Immunotherapy Likely New Standard in Advanced Esophageal Cancer Immunotherapy Likely New Standard in Advanced Esophageal Cancer

Nivolumab with chemotherapy or nivolumab with ipilimumab improved overall survival as compared with standard chemotherapy in advanced ESCC.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news